Automated Computer Tool Designs Ring-Shaped Drug Molecules From Small Molecules to Proteins | Research

The takeaway

Researchers built an automated computational platform that designs cyclic (ring-shaped) versions of drug molecules, improving their stability and binding properties.

4 molecular scales
The platform works across small molecules, peptides, PROTACs, and proteins — a rare breadth for a single design tool

What the researchers found

The automated platform successfully generates and ranks macrocyclic designs across molecular scales, from small molecules through peptides to PROTACs and proteins, using established chemical reactions and reagents.

Why it matters

Ring-shaped molecules often make better drugs than their linear counterparts — they bind more tightly, resist enzymatic breakdown, and can penetrate cells more easily. Automating their design could dramatically accelerate drug development timelines.

The numbers in context

Applicable to small molecules, peptides, PROTACs; validated prospectively and retrospectively

How the study worked

Computational approach using 3D protein-ligand structures as input, automated linker generation from a reaction library, geometric compatibility evaluation, and ranking by conformational stability. Validated with prospective and retrospective case studies.

Who was studied

Computational study with case studies

What this study cannot tell us

Computational predictions of binding and stability require experimental validation. The tool relies on known chemical reactions, potentially missing novel cyclization strategies. Manufacturing feasibility of proposed designs is not assessed.

How to read the evidence

Rated moderate because the computational approach is validated with both prospective and retrospective case studies, though real-world experimental confirmation of designs remains limited.

When this study was published

Published in 2020, this computational tool reflects the growing intersection of automation and drug design that continues to advance rapidly.

The bigger picture

As computational drug design tools become more sophisticated, the bottleneck in drug development shifts from molecular design to clinical testing. Automated macrocyclization could make previously "undruggable" targets accessible to peptide and small molecule therapeutics.

Questions still open

How well do the computationally predicted macrocyclic properties translate to experimental measurements?
Can this platform be integrated with machine learning to improve ranking accuracy over time?
What fraction of computationally proposed designs are synthetically feasible with current chemistry?

Common questions

Why are ring-shaped molecules better drugs than linear ones?

Ring-shaped (macrocyclic) molecules lock into their active shape, making them bind targets more tightly. They also resist enzymatic breakdown better, can penetrate cell membranes more easily, and sometimes achieve oral bioavailability — all advantages over their linear counterparts.

What are PROTACs and why does macrocyclization matter for them?

PROTACs are molecules designed to tag disease-causing proteins for destruction by the cell's own recycling machinery. Making them ring-shaped can improve their stability and cell penetration, which are key challenges for this emerging drug class.

Read the original research

Automated Design of Macrocycles for Therapeutic Applications: From Small Molecules to Peptides and Proteins.

Journal of medicinal chemistry, 63(20), 12100-12115

View on PubMed ↗Publisher’s paper ↗

Citation

Sindhikara, Dan; Wagner, Michael; Gkeka, Paraskevi; Güssregen, Stefan; Tiwari, Garima; Hessler, Gerhard; Yapici, Engin; Li, Ziyu; Evers, Andreas. (2020). Automated Design of Macrocycles for Therapeutic Applications: From Small Molecules to Peptides and Proteins.. Journal of medicinal chemistry, 63(20), 12100-12115. https://doi.org/10.1021/acs.jmedchem.0c01500